INTRODUCTION
The relative effectiveness of the various cinchona alkaloids in the treatment of malaria has been the subject of numerous investigations since the meeting of the Madras Commission in 1868 (1) . Without exception, studies undertaken prior to the recent war involved the appraisal of the comparative antimalarial activities of quinine, quinidine, cinchonine and cinchonidine on the basis of the oral dosage administered during one or another standard therapeutic regimen. Although the conclusions derived from these studies are not in complete agreement, it has been the general impression that all four of the cinchona alkaloids possess roughly equivalent antimalarial activities.
Therefore, it is surprising that quinine alone has come into general use in the suppression and treatment of malaria. The need for a further appraisal of the other cinchona alkaloids arose early in the course of the war because of the shortage of effective antimalarial drugs. Various cinchona barks containing the principal crystallizable alka- 1 The work described in this paper was done under a contract, recommended by the Committee on Medical Research, between the Office of Scientific Research and Development and New York University. 2 Portions of this work were presented at the meetings of the Federation of American Societies for Experimental Biology, March 11-15, 1946, Federation Proc., 1946, 5, 206 and 216 . 3 The authors express their thanks to the Malaria Study Section of the National Institute of Health for editorial assistance and for arrangements in regard to the publication of this paper. They are also grateful to the Abbott Laboratories, E. I. du Pont de Nemours and Company, Inc., E. R. Squibb and Sons, Eli Lilly and Company, Sharp and Dohme, and Wyeth, Inc., for contributing toward the publication costs. 4Captain, MC, AUS. loids other than quinine were potentially available in the Western hemisphere and offered a partial solution to the acute shortage, of antimalarial agents.
The studies reported in this communication are concerned with the physiological disposition, antimalarial activity and, to a lesser extent, the toxicity of the four principal cinchona alkaloids. The recent development of simple, reliable methods for estimating the concentrations of the alkaloids in biological materials permitted an examination of certain aspects of their pharmacology and therapeutic activity in terms of measured drug concentrations. Quantitative information of this type may be expected to establish a basis for the most effective use of these drugs in the treatment of malaria.
MATERIALS AND METHODS
In the estimation of the concentrations of cinchona alkaloids in plasma several general procedures were utilized. The fluorescent intensity of quinine was measured in an acidic, aqueous medium following protein precipitation with metaphosphoric acid (2) , quinidine by fluorimetry after extraction of the drug into ethylene dichloride (3). Cinchonine and cinchonidine were measured by the formation of an organic-soluble, water-insoluble complex of the alkaloid with methyl orange (4) . With the exception of the precipitation method, the final procedures utilized in estimating plasma drug concentrations appear to be specific for the parent compounds.
Ten to 20 per cent of the total fluorescent intensity obtained when the metaphosphoric acid precipitation method is applied to human plasma is contributed by metabolic products of quinine.
The therapeutic tests with blood-induced malaria were performed in accordance with standard procedures outlined in the preceding papers (5, 6) . Therapy was started on the fourth day after the onset of fever in vivax malaria and on the first or second day of fever in falciparum malaria. Stable plasma drug concentrations were maintained during the standard four-day (vivax) or six-80 day (falciparum) therapeutic period. The drugs were administered in soft gelatine capsules. All doses and plasma drug concentrations are reported in terms of the free base. The therapeutic results are classified as previously defined: Class I, indicating no certain effect from drug administration; Class II, a temporary suppression of parasitemia and/or fever; and Class III, a. "permanent" effect followed by a positive reinoculation procedure to establish evidence of continuing host-susceptibility.
PHYSIOLOGICAL DISPOSITION
The studies reported in this section were directed toward a limited description of the factors entering into the physiological disposition of the cinchona alkaloids. Particular emphasis was placed on the relationship between oral dosage regimens and the resultant plasma drug concentrations. In addition, data are presented concerning the absorption of the alkaloids from the gastrointestinal tract, their distribution in the body, metabolic alteration, and excretion.
Each of the drugs was administered according to several dosage schedules for periods of four days or more. Therapy consisted of an initial priming dose, usually one-half of the total daily dose, followed by small maintenance doses at fourto eight-hour intervals. Blood samples for the estimation of plasma drug concentrations were obtained several times daily throughout the period of therapy. The mean plasma drug concentrations With the other alkaloids, the increases are disproportionately small in relation to the dose. Peak plasma drug concentrations are achieved within one to three hours after a single oral dose of any one of the four drugs. Single oral doses of the alkaloid frequently produce plasma drug concentrations considerably lower than those obtained with soluble salts. However, on maintenance regimens, the equilibrium plasma concentration is the same with either alkaloid or salt. The plasma drug concentrations fall fairly rapidly after the termination of therapy, so that only negligible quantities of the drugs persist in the plasma beyond 24 hours.
The absorption of the four drugs from the gastro-intestinal tract is essentially complete, insofar as less than 5 per cent of the serially administered doses can be recovered from the stools. Nor is there evidence that appreciable metabolic alteration of the alkaloids occurs during their passage through the digestive tract. Small amounts of cinchonine may be incubated with stool at 37°C. and recovered quantitatively. That absorption from the gastro-intestinal tract is rapid and essentially complete is confirmed by the observation that plasma quinine and cinchonine concentrations obtained one to four hours after a single intravenous dose are approximately the same as when the drugs are administered by the oral route. Each of the subjects received a single oral dose of 0.3 gram quinine hydrochloride. A specimen of blood was obtained two hours after the dose, and the plasma was promptly removed by centrifugation.
Few direct observations on the extent to which the alkaloids are localized in tissues have been possible in man. The distribution of quinine in blood was examined in five subjects two hours after a single dose of 0.3 gram (Table II) . The concentration of quinine in the cellular elements of the blood was found to be less than 20 per cent of that in the plasma. Similar results were obtained with cinchonine. Thus, it is apparent that little localization of quinine or cinchonine occurs in either erythrocytes or leucocytes under the conditions of this experiment. Distribution studies in the chicken and dog (7, 8) have shown that the alkaloid concentrations in liver, spleen and other parenchymatous tissues are approximately 10 to 30 times that in the plasma . A lesser degree of localization occurs in skeletal and cardiac muscle, brain and other tissues. In man, the apparent volume of distribution of quinine within 15 minutes after an intravenous dose approximates the body weight. This may be regarded as indirect evidence for the limited tissue localization of quinine.
The total urinary excretion of unaltered cinchona alkaloids amounts to less than 5 per cent of the administered drug. Various metabolic products of the alkaloids are recovered from the urine and account for an additional 65 per cent of the total dose in the case of cinchonine, 20 per cent of quinine, but less than 5 per cent of either quinidine or cinchonidine (9, 10) . The fractions unaccounted for may represent metabolic products not readily identified. However, it is evident that renal excretion plays a minor role in regulating the plasma concentrations of the parent compounds.
In view of the essentially complete absorption, limited localization and limited excretion of the cinchona alkaloids, it becomes apparent that the fate of these drugs in the body is primarily one of metabolic alteration. As noted above, varying proportions of orally administered doses can be accounted for in the urine in the form of various metabolic products. Certain important metabolic products have been recovered from urine by selective extraction into organic solvents and isolated by means of the counter-current distribution technique (10) . Tentative identification by elementary analysis and comparison with known compounds indicates that each of the four alkaloids is oxidized to the corresponding carbostyril (2-hydroxyquinoline). In some instances, oxygen appears to be added to the quinuclidine portion of the molecule (9) . An enzyme which oxidizes each of the four alkaloids to its corresponding carbostyril has been isolated from rabbit liver (11) . This enzyme has properties similar to, and is not dissociable from the flavoprotein liver aldehyde oxidase. However, at the present time there is no evidence that this enzyme is responsible for the oxidation of the cinchona alkaloids in man.
Moreover, it appears probable that the exact metabolic pathway differs somewhat with the various alkaloids. The plasma levels of the various alkaloids achieved on maintenance dosage schedules reflect their relative rates of metabolic alteration (Table I) It is apparent that the plasma drug concentration which permanently interrupts the erythrocytic phase of either vivax or falciparum malaria differs significantly with the various alkaloids. Effective plasma concentrations of cinchonine are one-tenth to one-fiftieth those of quinine. Quinidine and cinchonidine are effective in concentra- It is evident from the data presented that any one of the four cinchona alkaloids will be generally effective in the management of clinical attacks of malaria. Totaquine, U.S.P., and other similar preparations, are cheap and available -in abundance. These contain varying proportions of each of the cinchona alkaloids and should be useful antimalarials unless the activities of the alkaloids are not additive. There is definite evidence that the effect of combinations of the different cinchona alkaloids is additive, both in the avian malarias (13) , and in vitro against falciparum parasites (14) . Totaquine has been utilized rather extensively in many endemic regions and has been reported to be effective. However, until recently, there was no definitive assay of the toxicity and antimalarial activity of this type of preparation (15) .
The data also indicate the importance of the various factors which determine the overall physiological disposition of each cinchona alkaloid. The cinchona alkaloids are localized in the tissues to some extent, but not nearly as much as is quinacrine (16) and the 4-aminoquinolines (17) , and there is no accumulation of the drugs in the body. The combined rates of metabolism and excretion of the alkaloids are such that dosage every six hours is required to assure the maintenance of effective plasma drug levels. Consequently, it would be unlikely that the cinchona alkaloids could be as effective or as simply administered for suppressive purposes, as can some of the newer synthetic antimalarial agents which can be given at weekly intervals.
The effective plasma level of cinchonine is considerably lower than that for any of the other cinchona alkaloids. However, its metabolism proceeds at such a rapid rate that plasmadrug levels achieved on cinchonine dosage are also lower than those of the other alkaloids. Since the first metabolic product of cinchonine is its carbostyril, it was possible that blocking the 2 position might re-sult in a compound that would be metabolized at a slower rate and which, therefore, might be a more effective antimalarial agent. This was not attempted with cinchonine, but the line of reasoning led to the development of a new series of synthetic compounds that were found to be active antimalarial agents. These compounds, 2-phenyl quinoline methanol derivatives, are readily synthesized but do not possess the advantages inherent in quinacrine and the 4-aminoquinolines (18) . BIBLIOGRAPHY 
